TY - JOUR
T1 - Targeted therapy of breast tumor by PLGA-based nanostructures
T2 - the versatile function in doxorubicin delivery
AU - Sonam Dongsar, Tenzin
AU - Tsering Dongsar, Tenzin
AU - Molugulu, Nagashekhara
AU - Annadurai, Sivakumar
AU - Wahab, Shadma
AU - Gupta, Neelima
AU - Kesharwani, Prashant
N1 - Funding Information:
The authors (Sivakumar Annadurai and Shadma Wahab) extend their appreciation to the Deanship of Scientific Research at King Khalid University for funding this work through Small group Research Project under grant number RGP1/220/44.
Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/9/15
Y1 - 2023/9/15
N2 - Breast carcinoma is a molecularly diverse illness, and it is among the most prominent and often reported malignancies in female across the globe. Surgical intervention, chemotherapy, immunotherapy, gene therapy, and endocrine treatment are among the currently viable treatment options for the carcinoma of breast. Chemotherapy is among the most prevalent cancer management strategy. Doxorubicin (DOX) widely employed as a cytostatic medication for the treatment of a variety of malignancies. Despite its widespread acceptance and excellent efficacy against an extensive line up of neoplasia, it has a variety of shortcomings that limit its therapeutic potential in the previously mentioned indications. Employment of nanoparticulate systems has come up as a unique chemo medication delivery strategy and are being considerably explored for the amelioration of breast carcinoma. Polylactic-co-glycolic acid (PLGA)-based nano systems are being utilized in a number of areas within the medical research and medication delivery constitutes one of the primary functions for PLGA given their inherent physiochemical attributes, including their aqueous solubility, biocompatibility, biodegradability, versatility in formulation, and limited toxicity. Herein along with the different application of PLGA-based nano formulations in cancer therapy, the present review intends to describe the various research investigations that have been conducted to enumerate the effectiveness of DOX-encapsulated PLGA nanoparticles (DOX-PLGA NPs) as a feasible treatment option for breast cancer.
AB - Breast carcinoma is a molecularly diverse illness, and it is among the most prominent and often reported malignancies in female across the globe. Surgical intervention, chemotherapy, immunotherapy, gene therapy, and endocrine treatment are among the currently viable treatment options for the carcinoma of breast. Chemotherapy is among the most prevalent cancer management strategy. Doxorubicin (DOX) widely employed as a cytostatic medication for the treatment of a variety of malignancies. Despite its widespread acceptance and excellent efficacy against an extensive line up of neoplasia, it has a variety of shortcomings that limit its therapeutic potential in the previously mentioned indications. Employment of nanoparticulate systems has come up as a unique chemo medication delivery strategy and are being considerably explored for the amelioration of breast carcinoma. Polylactic-co-glycolic acid (PLGA)-based nano systems are being utilized in a number of areas within the medical research and medication delivery constitutes one of the primary functions for PLGA given their inherent physiochemical attributes, including their aqueous solubility, biocompatibility, biodegradability, versatility in formulation, and limited toxicity. Herein along with the different application of PLGA-based nano formulations in cancer therapy, the present review intends to describe the various research investigations that have been conducted to enumerate the effectiveness of DOX-encapsulated PLGA nanoparticles (DOX-PLGA NPs) as a feasible treatment option for breast cancer.
KW - Breast cancer
KW - Chemotherapy
KW - Doxorubicin
KW - Nano systems
KW - Polylactic-co-glycolic acid
UR - http://www.scopus.com/inward/record.url?scp=85163797745&partnerID=8YFLogxK
U2 - 10.1016/j.envres.2023.116455
DO - 10.1016/j.envres.2023.116455
M3 - Review Article
C2 - 37356522
AN - SCOPUS:85163797745
SN - 0013-9351
VL - 233
JO - Environmental Research
JF - Environmental Research
M1 - 116455
ER -
